sinc
late
nineteenth
centuri
natur
produc
human
serum
immunoglobulin
use
passiv
immunotherapi
wide
rang
infecti
diseas
howev
owe
polyclon
variabl
natur
serum
immunoglobulin
therapi
mix
efficaci
also
hinder
ad
risk
bloodborn
pathogen
transmiss
mention
expens
practic
limit
largescal
product
human
blood
product
develop
hybridoma
technolog
milstein
group
allow
product
mous
monoclon
antibodi
defin
specif
neutral
capac
although
mous
monoclon
antibodi
revolution
biomed
scienc
prove
problemat
human
therapeut
use
short
serum
halflif
human
often
immunogen
low
effector
function
advent
technolog
produc
human
chimer
monoclon
antibodi
mani
problem
overcom
lead
gener
number
monoclon
antibodi
current
approv
clinic
use
recent
year
howev
develop
methodolog
produc
antigenspecif
monoclon
antibodi
directli
human
b
cell
allow
rapid
product
rise
isol
character
fulli
human
monoclon
antibodi
natur
gener
respons
autoantigen
pathogen
monoclon
antibodi
produc
toler
human
safeti
efficaci
relev
human
diseas
increas
compar
antibodi
gener
mice
speci
human
monoclon
antibodi
prove
invalu
improv
knowledg
natur
human
respons
pathogen
epitop
discoveri
human
monoclon
antibodi
also
high
potenti
serv
potent
therapeut
tool
rang
infecti
noninfecti
diseas
exampl
recent
thought
certain
singl
antibodi
capabl
neutral
broad
array
evolv
virus
influenza
viru
hiv
strain
extrem
rare
almost
imposs
isol
howev
highthroughput
technolog
clever
screen
process
care
select
infect
donor
allow
isol
character
sever
broadli
neutral
monoclon
antibodi
led
discoveri
newli
appreci
conserv
epitop
could
target
antibodymedi
therapi
andor
could
guid
vaccin
design
grow
optim
futur
work
lead
discoveri
addit
epitop
target
fight
mani
infecti
diseas
character
antibodi
also
led
new
insight
protein
structur
level
antibodi
gener
access
epitop
mask
immun
evas
mechan
togeth
scrutini
natur
antibodi
respons
led
unparallel
insight
uniqu
strategi
use
human
humor
system
neutral
pathogen
review
focu
human
monoclon
antibodi
deriv
directli
human
b
cell
gener
vivo
respons
specif
infect
rather
antibodi
deriv
synthet
immunoglobulin
recombin
librari
human
mous
system
although
latter
technolog
gener
valuabl
monoclon
antibodi
use
therapeut
cancer
metabol
diseas
autoimmun
diseas
review
elsewher
beyond
scope
review
summar
current
technolog
use
isol
human
monoclon
antibodi
describ
technolog
appli
understand
natur
immun
respons
influenza
viru
hiv
recent
advanc
isol
character
broadli
neutral
human
monoclon
antibodi
individu
expos
virus
elegantli
illustr
power
potenti
character
natur
humor
immun
respons
vari
approach
use
character
human
monoclon
antibodi
specif
influenza
viru
hiv
provid
crosssect
technolog
use
studi
human
monoclon
antibodi
use
knowledg
gain
howev
method
use
make
therapeut
improv
vaccin
infecti
diseas
hepat
c
viru
dengu
viru
pneumococc
staphylococc
bacteria
pathogen
antibodi
control
find
right
b
cell
needl
haystack
activ
b
cell
differenti
memori
b
cell
antibodysecret
cell
categor
shortliv
plasmablast
longliv
plasma
cell
memori
antibodysecret
b
cell
popul
use
gener
natur
deriv
antigenspecif
monoclon
antibodi
main
obstacl
gener
monoclon
antibodi
identifi
isol
b
cell
express
immunoglobulin
desir
specif
function
characterist
singlecel
level
broadli
speak
three
differ
strategi
use
fig
first
classic
mani
antibodi
isol
pan
phage
display
librari
construct
immunoglobulin
variabl
gene
immun
infect
individu
second
common
approach
b
cell
immort
follow
screen
vitro
cultur
antibodi
specif
recent
third
approach
develop
use
singlecel
sort
follow
clone
transcrib
immuno
globulin
gene
express
monoclon
antibodi
without
flow
cytometrybas
preselect
differ
select
method
less
amen
differ
b
cell
subtyp
phage
display
librari
success
gener
use
sort
memori
b
cell
total
peripher
blood
mononuclear
cell
popul
contain
b
cell
subtyp
includ
activ
naiv
b
cell
memori
b
cell
amen
b
cell
subset
immort
vitro
cultur
screen
antibodi
specif
although
recent
demonstr
singl
plasmablast
cultur
long
enough
time
secret
suffici
amount
antibodi
enabl
screen
multipl
antibodi
specif
without
immort
memori
b
cell
also
success
differenti
antibodysecret
cell
without
immort
secret
antibodi
screen
function
specif
detect
specif
b
cell
flow
cytometri
requir
express
immunoglobulin
cell
surfac
work
well
memori
b
cell
iga
mucos
longliv
plasma
cell
howev
select
method
less
success
igg
plasma
cell
plasmablast
peripher
blood
cell
low
surfac
immunoglobulin
level
plasmablast
activ
ongo
immun
respons
therefor
enrich
antibodi
specif
interest
cell
type
normal
isol
without
prescreen
antigenspecif
human
monoclon
antibodi
identifi
clone
express
provid
detail
isol
method
advantag
disadvantag
tabl
diseas
target
variou
approach
tabl
highthroughput
phage
display
technolog
phage
display
librari
singlechain
variabl
antibodi
fragment
scfv
antigenbind
fragment
fab
use
extens
identifi
clone
monoclon
antibodi
multitud
specif
construct
variabl
gene
librari
b
cell
isol
immun
individu
individu
post
infect
serv
way
search
highthroughput
manner
antibodi
produc
b
cell
respond
specif
pathogen
approach
use
isol
neutral
antibodi
specif
west
nile
viru
rabi
viru
sever
acut
respiratori
syndrom
sar
viru
hepat
viru
hiv
hantaviru
ebola
viru
yellow
fever
viru
hepat
c
viru
measl
viru
human
avian
influenza
viru
strain
well
pathogen
use
librari
gener
bone
marrow
peripher
blood
splenic
human
b
cell
immun
infect
individu
excel
method
obtain
neutral
antibodi
myriad
diseas
result
librari
antibodi
fragment
necessarili
faith
represent
physiolog
antibodi
gene
pair
antibodi
fragment
gener
random
pair
immunoglobulin
heavi
light
chain
variabl
region
clone
separ
thu
phage
display
certain
given
heavi
light
chain
pair
went
select
selftoler
howev
random
pair
also
creat
greater
divers
antibodi
shuffl
heavi
light
chain
repertoir
use
gener
higher
affin
antibodi
phage
display
also
make
difficult
draw
direct
conclus
rel
proport
particular
antibodi
specif
gain
understand
complet
repertoir
antigenspecif
b
cell
furthermor
antibodi
express
phage
display
system
may
mammalian
cell
owe
differ
protein
fold
posttransl
modif
caus
bia
isol
antibodi
mitig
problem
extent
system
also
develop
recombin
antibodi
fragment
express
cell
surfac
yeast
mammalian
cell
antigenspecif
cell
select
use
flowbas
method
respiratori
syncyti
viru
rsv
three
gener
approach
variat
therein
typic
use
isol
monoclon
antibodi
human
particular
method
use
depend
variou
factor
larg
driven
type
sampl
obtain
sampl
rare
specif
memori
b
cell
requir
higher
throughput
methodolog
phage
display
identifi
rarest
specif
b
epsteinbarr
viru
ebv
mediat
transform
b
cell
immort
strategi
use
sampl
immunolog
histori
known
c
instanc
effect
antigen
bait
avail
allow
detect
b
cell
specif
receptor
use
flow
cytometri
singlecel
express
clone
use
final
ongo
recent
immun
respons
vaccin
infect
popul
activ
plasmablast
contain
high
frequenc
specif
cell
use
gener
abund
human
monoclon
antibodi
express
clone
aid
activationinduc
cytidin
deaminas
cytosin
deaminas
catalys
pivot
step
antibodi
genediversif
reaction
rtpcr
type
pcr
rna
first
convert
doublestrand
dna
amplifi
b
cell
immort
typic
involv
cultur
total
peripher
blood
lymphocyt
sort
igg
memori
b
cell
fresh
frozen
sampl
presenc
ebv
togeth
ligand
andor
allogen
irradi
mononuclear
cell
provid
costimulatori
signal
condit
b
cell
prolifer
secret
antibodi
week
two
later
supernat
cultur
cell
test
antigen
bind
andor
viral
neutral
b
cell
produc
anti
bodi
interest
clone
limit
dilut
screen
desir
reactiv
singlecel
level
individu
immunoglobulin
heavi
light
chain
pair
clone
sequenc
ebvtransform
b
cell
clone
also
fuse
myeloma
cell
gener
hybridoma
facilit
stabl
product
high
level
antibodi
kwakkenbo
et
al
took
differ
approach
immort
b
cell
transduc
memori
b
cell
obtain
peripher
blood
retroviru
encod
antiapoptot
factor
b
cell
lymphoma
bclxl
presenc
ligand
transduc
cell
differenti
longliv
antibodysecret
cell
still
express
b
cell
receptor
cell
surfac
thu
allow
select
antigen
specif
flow
cytometri
screen
secret
antibodi
cell
also
maintain
activationinduc
cytidin
deaminas
aid
mediat
mutat
activ
although
vitro
mutat
may
sourc
antibodi
clone
instabl
may
also
lead
product
subclon
higher
affin
immort
memori
b
cell
highthroughput
screen
antigenspecif
b
cell
allow
isol
rare
b
cell
memori
pool
month
even
year
antigen
exposur
exampl
ebvmedi
immort
memori
b
cell
popul
isol
older
individu
gener
immun
system
decad
earlier
allow
isol
antibodi
specif
influenza
viru
strain
longer
circul
includ
pandem
spanish
flu
strain
pandem
strain
circul
sinc
drawback
approach
involv
screen
larg
number
b
cell
obtain
monoclon
antibodi
desir
specif
typic
ten
thousand
memori
b
cell
cultur
screen
obtain
less
ten
specif
b
cell
import
advanc
human
monoclon
antibodi
technolog
use
singlecel
revers
transcript
pcr
rtpcr
isol
cognat
immunoglobulin
heavi
light
chain
variabl
gene
singl
b
cell
sort
flow
cytometri
gene
could
clone
express
eukaryot
cell
line
approach
allow
human
monoclon
antibodi
obtain
even
rare
highli
discret
b
cell
subpopul
provid
cell
identifi
flow
cytometri
wardemann
et
al
first
appli
approach
understand
tolerogen
select
develop
human
b
cell
subpopul
methodolog
subsequ
appli
understand
human
b
cell
select
multipl
situat
healthi
immunocompromis
individu
central
compon
antigen
bait
plasmablast
approach
describ
altern
screen
antibodi
secret
antigenspecif
b
cell
vitro
antigen
bait
involv
use
fluoresc
label
antigen
first
sort
antigenspecif
b
cell
flow
cytometri
first
use
combin
b
cell
immort
approach
combin
great
effect
singlecel
express
clone
method
involv
clone
variabl
region
amplifi
singl
antigenspecif
cell
mammalian
express
vector
contain
constant
region
gene
vector
use
transfect
cell
antibodi
product
purif
monoclon
antibodi
produc
test
antigen
specif
neutral
capac
antigen
bait
quit
success
obtain
hivspecif
human
monoclon
antibodi
igg
memori
b
cell
pool
infect
donor
use
envelop
spike
protein
probe
furthermor
longliv
iga
plasma
cell
mucos
tissu
line
intestin
express
immuno
globulin
cell
surfac
antigen
bait
allow
antigenspecif
plasma
cell
isol
intestin
biopsi
gener
rotavirusspecif
human
monoclon
antibodi
healthi
individu
transglutaminas
human
monoclon
antibodi
patient
coeliac
diseas
detect
antigenspecif
monoclon
antibodi
use
flow
cytometri
limit
b
cell
type
express
immuno
globulin
cell
surfac
avail
highli
specif
stabl
antigen
act
probe
howev
allow
effici
highli
select
isol
b
cell
cell
sort
flow
cytometri
produc
immuno
globulin
desir
specif
although
method
primarili
screen
bind
specif
function
characterist
exemplifi
studi
hivspecif
human
monoclon
antibodi
see
b
cell
express
neutral
antibodi
preferenti
target
cleverli
design
antigen
probe
owe
resist
shortliv
plasmablast
ebvmedi
immort
low
surfac
immunoglobulin
express
level
screen
immunoglobulin
specif
b
cell
type
monoclon
level
difficult
although
efficaci
vaccin
tradit
analys
test
polyclon
serum
immunoglobulin
respons
clone
express
immunoglobulin
plasmablast
monoclon
level
provid
new
level
resolut
ongo
immun
respons
valuabl
sourc
therapeut
relev
human
monoclon
antibodi
observ
transient
often
larg
popul
antigenspecif
plasmablast
peripher
blood
day
vaccin
creat
opportun
sort
clone
immunoglobulin
gene
plasmablast
major
immunoglobulin
antigen
specif
use
gene
human
monoclon
antibodi
product
approach
particularli
use
examin
ongo
immun
respons
vaccin
time
antigen
exposur
well
defin
exampl
method
success
analys
immun
respons
influenza
tetanu
anthrax
vaccin
approach
work
best
freshli
isol
cell
although
frozen
sampl
massiv
parallel
highthroughput
nonsang
method
sequenc
use
surviv
plasmablast
neg
affect
freez
thaw
process
random
clone
monoclon
antibodi
activ
plasmablast
without
prescreen
specif
also
ineffici
start
popul
contain
cell
bind
antigen
interest
prescreen
howev
inher
bia
obtain
inform
antibodi
respons
given
pathogen
autoantigen
thu
isol
care
character
plasmablast
provid
unexpect
novel
insight
immun
respons
final
variou
highthroughput
technolog
develop
gener
comprehens
pictur
human
b
cell
respons
method
describ
point
result
isol
character
small
subset
antigenspecif
b
cell
one
promis
approach
use
nextgener
sequenc
exhaust
sequenc
entir
b
cell
repertoir
nextgener
sequenc
use
look
gener
characterist
immunoglobulin
divers
usag
cognat
heavi
light
chain
pair
inform
avail
howev
immunoglobulin
variabl
gene
sequenc
deriv
nextgener
sequenc
given
individu
mine
b
cell
sequenc
clonal
relat
isol
character
use
monoclon
antibodi
method
describ
provid
inform
clonal
divers
affin
matur
antigenspecif
b
cell
vari
time
point
b
cell
popul
sequenc
longev
particular
b
cell
specif
interest
b
cell
subset
contain
specif
also
determin
pair
mass
spectrometri
data
obtain
digest
serum
antibodi
fragment
nextgener
sequenc
inform
antibodysecret
cell
also
use
recent
resolv
monoclon
level
polyclon
serum
respons
thu
character
antibodi
respons
cellular
serolog
level
individu
microarray
technolog
also
develop
function
profil
antibodysecret
cell
singlecel
level
epitop
map
serolog
respons
new
highthroughput
technolog
potenti
increas
effici
produc
human
monoclon
antibodi
resolut
antibodi
character
choos
method
choic
method
isol
human
monoclon
antibodi
determin
sever
factor
import
factor
includ
expertis
particular
investig
primari
purpos
make
human
monoclon
antibodi
furthermor
state
knowledg
alreadi
exist
antibodi
respons
particular
diseas
often
dictat
appropri
approach
intent
isol
therapeut
purpos
human
monoclon
antibodi
highest
possibl
efficaci
neutral
given
pathogen
highli
target
screen
memori
b
cell
specif
bind
function
characterist
like
appropri
approach
screen
accomplish
phage
display
test
antibodi
secret
vitro
cultur
system
flow
cytometrybas
select
immun
individu
howev
purpos
first
fulli
character
spectrum
b
cell
repertoir
respond
given
antigen
particular
diseas
broader
less
select
criteria
use
clone
human
monoclon
antibodi
memori
antibodysecret
cell
morerandom
sampl
human
monoclon
antibodi
repertoir
provid
valuabl
inform
protect
nonprotect
immun
respons
vaccin
infect
lessselect
approach
also
use
character
novel
neutral
epitop
defin
autoantibodi
aris
autoimmun
diseas
human
monoclon
antibodi
isol
character
inform
gain
antibodi
inform
subsequ
studi
allow
finetun
select
criteria
use
isol
new
relev
human
monoclon
antibodi
b
cell
respons
viral
infect
particularli
well
studi
use
combin
technolog
describ
illustr
well
complementari
inform
variou
method
provid
describ
detail
isol
natur
produc
human
monoclon
antibodi
use
differ
method
expand
knowledg
human
immun
respons
evolv
viral
pathogen
influenza
viru
hiv
fig
influenza
viru
continu
evolv
adapt
escap
protect
immun
make
difficult
gener
univers
vaccin
could
provid
perman
protect
influenza
viru
strain
worldwid
influenza
caus
hundr
thousand
death
year
owe
local
influenza
epidem
pandem
infect
larg
portion
human
popul
infect
avian
influenza
viru
result
particularli
high
mortal
rate
event
led
renew
fear
influenza
pandem
similar
spanish
flu
kill
million
peopl
great
deal
interest
find
protect
monoclon
antibodi
act
passiv
immunotherapi
use
identifi
epitop
target
provid
broad
protect
across
wide
diverg
influenza
strain
antibodi
neutral
influenza
viru
bind
either
haemagglutinin
neuraminidas
surfac
glycoprotein
inhibit
viral
entri
exit
respect
differ
known
haemagglutinin
subtyp
influenza
viru
strain
subdivid
two
main
phylogenet
group
group
group
subunit
haemagglutinin
predominantli
form
globular
head
contain
sialic
acid
bind
site
subunit
primarili
form
stalk
membraneattach
portion
molecul
fig
except
broadli
neutral
monoclon
antibodi
isol
immun
mous
region
surround
bind
site
host
sialic
acid
receptor
inhibit
viral
attach
cell
surfac
owe
continu
genet
evolut
region
haemagglutinin
howev
antibodi
specif
head
region
usual
bind
restrict
subset
viral
strain
howev
two
import
paper
publish
determin
structur
two
differ
broadli
neutral
antibodi
specif
subunit
antibodi
isol
phage
display
b
cell
peopl
vaccin
influenza
synthet
librari
two
antibodi
prevent
structur
rearrang
haemagglutinin
necessari
fusion
viral
envelop
intern
cell
membran
portion
haemagglutinin
stem
region
highli
conserv
across
influenza
viru
strain
antibodi
neutral
strain
clade
current
substanti
effort
influenza
vaccin
commun
preferenti
target
epitop
discoveri
broadli
neutral
antibodi
prompt
search
character
addit
broadli
neutral
human
monoclon
antibodi
specif
influenza
viru
use
b
cell
individu
receiv
annual
season
trival
influenza
vaccin
contain
b
strain
ebvimmort
memori
b
cell
broadli
neutral
specif
identifi
screen
mono
clonal
antibodi
could
neutral
strain
screen
neutral
viral
strain
present
vaccin
investig
could
identifi
b
cell
antibodi
abl
bind
region
conserv
diverg
strain
way
independ
human
monoclon
antibodi
bound
virus
clade
isol
well
antibodi
recogn
clade
virus
one
monoclon
antibodi
bound
stem
portion
haemagglutinin
one
headbind
antibodi
restrict
viru
strain
neutral
capabl
anoth
studi
use
novel
approach
cultur
singl
plasma
cell
isol
week
either
influenza
viru
infect
administr
trival
vaccin
author
screen
singlecel
cultur
supernat
presenc
immunoglobulin
capabl
bind
group
group
haema
gglutinin
although
low
antibodi
concentr
supernat
obtain
use
method
may
preclud
detect
lowaffin
antibodi
suffici
amount
antibodi
gener
highaffin
maxim
chanc
identifi
relev
human
monoclon
antibodi
potent
broad
reactiv
variant
form
particular
viru
pathogen
number
issu
must
taken
consider
studi
design
factor
summar
figur
detail
within
bodi
text
includ
follow
first
appropri
cohort
must
chosen
hiv
longterm
nonprogressor
influenza
pandem
survivor
current
recent
infect
individu
vaccin
individu
peopl
wider
breadth
higher
potenc
serum
neutral
gener
popul
b
second
appropri
methodolog
must
chosen
gener
librari
monoclon
antibodi
c
third
relev
resourc
reagent
methodolog
must
appli
character
activ
antibodi
isol
exampl
character
includ
screen
appropri
bind
characterist
use
enzymelink
immunosorb
assay
elisa
surfac
plasmon
reson
determin
breadth
potenc
neutral
activ
vitro
test
vivo
efficaci
protect
antibodi
anim
model
map
epitop
escapemut
analysi
targetantigen
mutagenesi
competit
assay
use
monoclon
antibodi
known
specif
function
assay
xray
crystallographi
spacefil
diagram
denot
structur
antibodi
fab
fragment
bound
influenza
viru
haemagglutinin
exemplifi
epitop
determin
use
crystallographi
biolog
inform
glean
analys
highli
uniqu
antibodi
variabl
gene
sequenc
use
understand
immun
respons
well
identifi
addit
antibodi
similar
specif
differ
fine
specif
efficaci
owe
differenti
accumul
immunoglobulin
somat
mutat
graph
depict
typic
nucleotid
sequenc
data
viral
envelop
clone
screen
multipl
antigen
use
approach
abl
identifi
one
antibodi
bound
group
group
influenza
viru
strain
howev
natur
emerg
broadli
neutral
antibodi
appear
rare
antibodi
bound
group
one
obtain
among
plasma
cell
differ
donor
previous
select
high
heterosubtyp
serum
antibodi
titr
furthermor
antibodi
could
identifi
immort
memori
b
cell
donor
screen
emerg
pandem
strain
creat
interest
situat
abil
clone
character
specif
plasmablast
peripher
blood
could
appli
pandem
strain
aros
reassort
swine
human
viral
compon
haemagglutinin
neuraminidas
protein
deriv
swine
influenza
viru
strain
close
resembl
pandem
viru
diverg
two
viru
strain
major
antigen
site
haemagglutinin
head
contrast
diverg
pandem
strain
recent
season
vaccin
strain
influenza
name
surprisingli
older
individu
like
expos
strain
fewer
incid
pandem
influenza
infect
younger
peopl
soon
becam
appar
howev
analys
plasmablast
respons
rel
young
individu
expos
pandem
strain
much
higher
percentag
respond
cell
broadli
reactiv
across
viral
strain
contrast
respons
prepandem
season
strain
antibodi
typic
bound
antigen
diverg
globular
head
antibodi
induc
pandem
strain
bound
conserv
region
haemagglutinin
stem
addit
broad
reactiv
antibodi
immunoglobulin
variabl
region
gene
pandem
plasmablast
highli
mutat
indic
plasmablast
probabl
aros
memori
b
cell
heterosubtyp
specif
known
exist
low
frequenc
owe
past
exposur
season
strain
taken
togeth
data
indic
exposur
antigen
novel
strain
influenza
viru
elicit
antibodi
respons
bias
toward
antibodi
specif
conserv
region
haemagglutinin
name
stem
region
observ
provid
import
proof
principl
broadli
protect
even
panprotect
antibodi
respons
influenza
viru
could
inde
elicit
right
immunogen
subsequ
studi
demonstr
similar
respons
induc
human
respons
pandem
strain
vaccin
hiv
hiv
intens
studi
sinc
first
isol
effect
vaccin
remain
elus
owe
cell
tropism
immun
evas
capac
viru
particular
develop
broadli
neutral
antibodi
viral
envelop
contain
spike
compos
surfac
trimer
transmembran
trimer
fig
imped
high
variabl
expos
epitop
structur
inaccess
conserv
region
owe
part
heavi
glycan
shield
rel
difficulti
gener
human
monoclon
antibodi
rariti
broadli
neutral
antibodi
infect
individu
recent
natur
occur
broadli
neutral
antibodi
specif
conserv
region
hiv
describ
sinc
howev
rapid
success
paper
describ
newli
isol
broadli
neutral
antibodi
hivinfect
patient
indic
potent
broadli
neutral
antibodi
natur
gener
provid
import
insight
crucial
epitop
might
facilit
develop
hiv
vaccin
way
epitop
might
target
success
isol
broadli
neutral
antibodi
gener
respons
human
hiv
infect
recent
year
due
care
select
infect
donor
high
serum
titr
broadli
neutral
antibodi
due
target
approach
isol
larg
quantiti
hivspecif
neutral
memori
b
cell
first
highthroughput
attempt
began
screen
serum
donor
high
neutral
titr
next
simek
et
al
chose
one
donor
activ
differenti
igg
memori
b
cell
antibodysecret
cell
screen
cultur
supernat
antibodi
capabl
bind
envelop
protein
neutral
activ
screen
two
broadli
neutral
monoclon
antibodi
isol
higher
neutral
activ
broadli
neutral
antibodi
isol
thu
far
bind
two
broadli
neutral
antibodi
map
conserv
region
hiv
subunit
contain
variabl
loop
residu
nlink
glycan
screen
memori
b
cell
anoth
four
infect
donor
yield
sever
addit
broadli
neutral
antibodi
even
potent
broadli
neutral
capabl
also
bound
variabl
loop
epitop
corti
et
al
screen
ebvimmort
memori
b
cell
hivinfect
donor
neutral
serum
antibodi
efficaci
ebv
immort
lower
b
cell
hivposit
patient
b
cell
healthi
donor
b
cell
clone
isol
one
potent
broad
neutral
capabl
wu
et
al
use
highli
target
flow
cytometrybas
approach
isol
broadli
neutral
antibodi
memori
b
cell
infect
individu
base
epitop
bound
wellcharacter
broadli
neutral
antibodi
bind
bind
site
stabil
core
construct
contain
major
contact
site
antigen
region
nonneutr
antibodi
bind
remov
use
resurfac
protein
term
protein
point
mutat
bind
site
bait
investig
sort
memori
b
cell
specif
total
million
peripher
blood
mononuclear
cell
one
donor
whose
serum
shown
bind
prescreen
individu
sort
b
cell
directli
amplifi
clone
immunoglobulin
heavi
light
chain
gene
made
human
monoclon
antibodi
three
human
monoclon
antibodi
bound
two
clonal
relat
clone
bound
rel
high
affin
neutral
impress
breadth
hiv
isol
author
later
use
approach
two
donor
identifi
potent
broadli
neutral
antibodi
likewis
bound
bind
site
ref
scheid
et
al
use
similar
approach
screen
memori
b
cell
hiv
bind
instead
target
b
cell
specif
bound
bind
site
use
solubl
form
complet
trimer
env
spike
bait
flow
cytometri
screen
memori
b
cell
six
patient
prescreen
broadli
neutral
antibodi
blood
highli
effici
method
b
cell
monoclon
antibodi
produc
specif
hiv
hivbind
human
monoclon
antibodi
made
clonal
distinct
neutral
narrow
rang
hiv
isol
bind
spectrum
epitop
studi
demonstr
wide
rang
neutral
epitop
exist
consid
specif
hiv
isol
human
monoclon
antibodi
use
cocktail
high
concentr
togeth
neutral
broad
array
hiv
isol
although
singl
monoclon
antibodi
neutral
breadth
monoclon
antibodi
previous
describ
howev
alter
primer
use
amplifi
immunoglobulin
gene
reproduc
high
mutat
level
hivspecif
broadli
neutral
antibodi
use
moretarget
probe
compos
core
glycoprotein
stabil
conform
lack
variabl
loop
six
clonal
distinct
broadli
neutral
antibodi
identifi
one
monoclon
antibodi
potent
variant
broadli
neutral
antibodi
isol
patient
use
bait
case
hiv
field
progress
simpli
isol
character
natur
produc
broadli
neutral
antibodi
group
mention
gone
comprehens
studi
dna
sequenc
protein
structur
level
antibodi
gener
featur
essenti
potenc
scheid
et
al
use
primer
specif
immunoglobulin
variabl
heavi
chain
gene
broadli
neutral
antibodi
amplifi
larg
number
addit
cdna
transcript
relat
clone
longliv
bone
marrow
plasma
cell
hivinfect
donor
provid
inform
variabl
magnitud
clonal
variant
test
presenc
b
cell
certain
specif
differ
b
cell
effector
popul
wu
et
al
perform
nextgener
sequenc
memori
b
cell
cdna
focus
immunoglobulin
variabl
heavi
chain
gene
obtain
thousand
sequenc
ident
origin
b
cell
immunoglobulin
gene
sort
flow
cytometri
make
monoclon
antibodi
variant
examin
function
characterist
remark
converg
affin
matur
conserv
residu
import
neutral
wide
rang
hiv
variant
identifi
protein
structur
level
diskin
et
al
compar
structur
complex
hiv
led
silico
design
antibodi
even
greater
breadth
neutral
activ
either
origin
form
togeth
eleg
studi
serv
illustr
advantag
disadvantag
differ
strategi
use
isol
natur
produc
human
monoclon
antibodi
use
specif
probe
design
base
lesson
learnt
previous
isol
neutral
nonneutr
monoclon
antibodi
wu
et
al
abl
isol
broadli
neutral
antibodi
recogn
highli
conserv
epitop
crucial
viral
infect
walker
et
al
chose
screen
neutral
capac
memori
b
cell
base
select
bind
antibodi
specif
region
hiv
spike
way
obtain
broadli
neutral
antibodi
recogn
conserv
glycanprotein
quarternari
structur
variabl
loop
region
thought
poor
target
broadli
neutral
antibodi
owe
mostli
variabl
residu
use
bind
hiv
spike
select
criterion
scheid
et
al
mouquet
et
al
focu
identifi
broadli
neutral
b
cell
instead
produc
inform
divers
epitop
target
neutral
b
cell
respons
hiv
widen
list
epitop
need
consid
design
vaccin
immunogen
also
provid
larg
dataset
glean
common
featur
hivspecif
antibodi
set
groundwork
comparison
b
cell
respons
individu
differ
clinic
outcom
challeng
induc
neutral
antibodi
continu
focu
best
way
identifi
character
natur
produc
human
monoclon
antibodi
ongo
challeng
take
advantag
inform
learn
although
human
monoclon
antibodi
might
certainli
excit
potenti
therapeut
highest
impact
public
health
would
achiev
design
vaccin
natur
elicit
antibodi
bind
key
epitop
review
detail
elsewher
sever
gener
approach
consid
exemplifi
b
cell
respons
might
target
new
vaccin
one
biggest
challeng
increas
breadth
protect
provid
vaccin
neutral
larg
span
evolv
viral
strain
howev
isol
neutral
human
monoclon
antibodi
individu
mean
readili
induc
similar
antibodi
vaccin
individu
immun
respons
individu
dramat
affect
variou
factor
includ
immun
vaccin
histori
genet
background
geograph
region
ethnic
diet
concurr
infect
age
factor
caus
immunocompromis
exampl
although
individu
clearli
respond
pandem
infect
vaccin
particularli
broadspectrum
respons
other
studi
highli
specif
respons
pandem
strain
broadli
protect
respons
probabl
elicit
memori
b
cell
specif
diverg
influenza
strain
possibl
peopl
highli
target
respons
preexist
memori
b
cell
influenza
viru
case
hiv
estim
infect
individu
broadli
neutral
antibodi
open
question
whether
peopl
develop
antibodi
differ
preexist
b
cell
repertoir
ineffici
b
cell
activ
hivspecif
broadli
neutral
antibodi
part
highli
mutat
often
polyreact
therefor
gener
broadli
neutral
antibodi
may
requir
extens
antigen
exposur
multipl
round
hypermut
affin
matur
toler
mechan
individu
may
also
prevent
polyreact
b
cell
reach
matur
import
point
determin
vaccin
approach
hiv
explor
event
key
first
step
identifi
relev
epitop
need
target
understand
detail
immun
process
requir
natur
product
neutral
antibodi
use
variou
approach
discuss
effici
clone
human
monoclon
antibodi
continu
provid
crucial
insight
final
develop
vaccin
immun
pathogen
thu
far
evad
effort
